MSV-100-IV Pediatric

Trial Results: MSV-100-IV Pediatric Expanded Access Program (EAP) in Steroid Refractory Acute Graft Versus Host Disease (Protocol 275)

Use of our MSC-100-IV, resulted in a clear, significant survival benefit among responding pediatric BMT recipients with SR-aGVHD. In the additional analysis of the first 160 patients completed, 64% achieved a response at day 28. Among responders, 81% were alive at day 100, compared to 39% survival at 100 days among non- responders (p<0.0001, log rank test). Day 28 response to MLC treatment was a significant predictor of improved day 100 survival (p<.001). The EAP protocol and data generated for MSC-100-IV represent the largest prospective program of its kind in pediatric patients with SR-aGVHD.